The role of Pazopanib in Soft Tissue Sarcoma: A comprehensive review of the literature

Abstract

INTRODUCTION: Sarcomas are a rare and heterogeneous group of tumours of mesenchymal origin. Single agent pazopanib showed activity in a phase II clinical trial designed to screen various soft tissue sarcoma subtypes [10] and a phase III [11] clinical trial followed resulting in FDA approval in 2012 for use in metastatic soft tissue sarcoma exposed to prior chemotherapy.

Keywords

• soft tissue sarcoma
• pazopanib
• sts
• vegfr2
• tkis
• angiogenesis
• advanced sarcoma treatment
• targetted therapy for sarcoma